Evidence map›Paper›PMID 40386896›Full record

ArticlePM & R : the journal of injury, function, and rehabilitation2025

Predicting medical prognosis in patients with glioblastoma during inpatient rehabilitation using bed mobility function.

Tomasz Gruchala, Christopher W Lewis, Kathryn Abplanalp, Prakash Jayabalan, Theresa L Walunas, Jodi L Johnson, Derek A Wainwright, Rimas V Lukas, Gayle Spill, Ishan Roy

Abstract read
In one paragraph

Article in PM & R : the journal of injury, function, and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tomasz GruchalaFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID 0009-0004-1772-6681
Christopher W LewisDepartment of Rehabilitation Medicine, University of Washington, Seattle, Wasington, USA.
Kathryn AbplanalpShirley Ryan Ability Lab, Chicago, Illinois, USA.
Prakash JayabalanFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID 0000-0002-0369-2896
Theresa L WalunasFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Jodi L JohnsonFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Derek A WainwrightDepartment of Cancer Biology, Stritch School of Medicine, Loyola University, Maywood, Illinois, USA.
Rimas V LukasFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Gayle SpillFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Ishan RoyFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.ORCID 0000-0002-9109-0421

Funding

IDO1 and Immunotolerance in GlioblastomaR01NS097851 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHILTZ, GARY E, WAINWRIGHT, DEREK ALAN · 2016 to 2025
$4.6M
Extratumoral biological determinants that decrease survival in older adults with glioblastomaR01NS129835 · NINDS · LOYOLA UNIVERSITY CHICAGO · PI Derek Alan Wainwright · 2023 to 2026
$1.5M
Muscle Fibrosis in CachexiaK08AR081391 · NIAMS · REHABILITATION INSTITUTE OF CHICAGO D/B/A SHIRLEY RYAN ABILITYLAB · PI Ishan Roy · 2022 to 2026
$846k
The interaction of IDO and Tregs Leads to Immunosuppression in GliomaR00NS082381 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2014 to 2016
$735k
Aging, immunosenescence and glioblastomaK02AG068617 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2020 to 2024
$688k
The interaction of IDO and Tregs Leads to Immunosuppression in GliomaK99NS082381 · NINDS · UNIVERSITY OF CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2013 to 2014
$173k
The role of IDO and Th17 in an experimental mouse model of gliomaF32NS073366 · NINDS · UNIVERSITY OF CHICAGO · PI WAINWRIGHT, DEREK ALAN · 2011 to 2012
$86k
H foundationNIAMS NIH HHS K08 AR081391NIAMS NIH HHS K08AR081391NIA NIH HHS K02 AG068617NINDS NIH HHS F32 NS073366NINDS NIH HHS K99 NS082381NINDS NIH HHS R00 NS082381NINDS NIH HHS R01 NS097851NINDS NIH HHS R01 NS129835
6 · The paper itself

Abstract

backgroundDetermining appropriate suitability and goals for inpatient rehabilitation of patients with glioblastoma, isocitrate dehydrogenase-wildtype (GBM) requires real-time prognostic information. Functional measures, such as bed mobility, are standardized scores that can be assessed by members of the care team at the bedside and may aid medical prognostication.

objectiveTo analyze the association between bed mobility function during inpatient rehabilitation and 6-month survival post rehabilitation in people with GBM.

designRetrospective cohort study.

settingAcademic inpatient rehabilitation facility (IRF). PATIENTS: One hundred seventy patients with GBM admitted to an IRF over 4.5 years.

interventionsNot applicable.

main outcome measureSurvival 6 months post rehabilitation, regardless of disease progression or events.

resultsUnivariate analyses showed admission (odds ratio [OR] = 1.63, 95% confidence interval [CI] 1.23-2.20; p < .001), discharge (OR = 1.72, 95% CI 1.39-2.16; p <. 001) and gain in bed mobility (OR = 1.64, 95%CI 1.26-2.20; p < .001) were associated with survival. In multivariate analyses adjusting for demographic and clinic variables, admission (OR = 1.91, 95% CI 1.39-2.69; p < .001), discharge (OR = 1.72, 1.38-2.19; p < .001), and gain in bed mobility (OR = 1.62, 95% CI 1.20-2.22; p = .002) were each independently associated with survival. Bed mobility was also independently associated with survival compared to other standard functional independence measures collected in IRF at discharge (OR = 1.88, 95% CI 1.14-3.23; p = .017) and for gain (OR = 1.65, 95% CI 1.10-2.53; p = .018). There was a significant difference in survival between patients with admission bed mobility scores of ≤1 or ≥2 (HR = 3.68, p < .001), discharge scores of ≤1 or ≥2 (HR = 5.72, p<. 001), or a gain of ≤0 or ≥1 (HR = 3.13, p < .001).

conclusionsBed mobility function may serve as a predictor of survival in GBM, suggesting that it could be used during inpatient rehabilitation to help determine functional goals for patients with GBM.

Indexed as

BedsBrain NeoplasmsGlioblastomaInpatientsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRehabilitation CentersRetrospective StudiesSurvival Rate

Identifiers

PMID40386896
PMCPMC12354043

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.